Which has preferable earnings & valuation, TLX or ORIC?

Telix Pharmaceuticals has higher revenue and earnings than Oric Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.50 -$7.12M N/A N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A

Is TLX or ORIC more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A Oric Pharmaceuticals N/A -35.33% -33.31%

Which has better earnings and valuation, DYN or ORIC?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A

Is DYN or ORIC more profitable?

Oric Pharmaceuticals' return on equity of -35.33% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -58.28% -46.77% Oric Pharmaceuticals N/A -35.33% -33.31%

Oric Pharmaceuticals (ORIC) Competitors

$9.53 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$9.62 +0.09 (+0.99%)

As of 05:22 AM Eastern

Compare

ORIC vs. BEAM, NAMS, TLX, ARQT, and DYN

Should you buy Oric Pharmaceuticals stock or one of its competitors? MarketBeat compares Oric Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oric Pharmaceuticals include Beam Therapeutics (BEAM), NewAmsterdam Pharma (NAMS), Telix Pharmaceuticals (TLX), Arcutis Biotherapeutics (ARQT), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry.

How does Oric Pharmaceuticals compare to Beam Therapeutics?

Oric Pharmaceuticals (NASDAQ:ORIC) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Oric Pharmaceuticals currently has a consensus price target of $18.92, suggesting a potential upside of 98.50%. Beam Therapeutics has a consensus price target of $46.83, suggesting a potential upside of 34.53%. Given Oric Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Oric Pharmaceuticals is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Beam Therapeutics had 5 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 6 mentions for Beam Therapeutics and 1 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 1.89 beat Beam Therapeutics' score of 0.73 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Oric Pharmaceuticals	Very Positive
Beam Therapeutics	Positive

Oric Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market.

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Oric Pharmaceuticals has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Beam Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Beam Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Beam Therapeutics	$139.74M	25.63	-$79.99M	-$0.68	N/A

Summary

Beam Therapeutics beats Oric Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to NewAmsterdam Pharma?

Oric Pharmaceuticals (NASDAQ:ORIC) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

In the previous week, NewAmsterdam Pharma had 3 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 1 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 1.89 beat NewAmsterdam Pharma's score of 0.43 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Oric Pharmaceuticals	Very Positive
NewAmsterdam Pharma	Neutral

Oric Pharmaceuticals has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
NewAmsterdam Pharma	$22.50M	172.70	-$203.82M	-$1.79	N/A

Oric Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market.

Oric Pharmaceuticals has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Oric Pharmaceuticals presently has a consensus target price of $18.92, indicating a potential upside of 98.50%. NewAmsterdam Pharma has a consensus target price of $48.60, indicating a potential upside of 46.21%. Given Oric Pharmaceuticals' higher probable upside, research analysts clearly believe Oric Pharmaceuticals is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Oric Pharmaceuticals beats NewAmsterdam Pharma on 9 of the 16 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Oric Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Telix Pharmaceuticals has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

95.1% of Oric Pharmaceuticals shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Telix Pharmaceuticals currently has a consensus price target of $21.13, indicating a potential upside of 98.17%. Oric Pharmaceuticals has a consensus price target of $18.92, indicating a potential upside of 98.50%. Given Oric Pharmaceuticals' higher probable upside, analysts plainly believe Oric Pharmaceuticals is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Telix Pharmaceuticals' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

Telix Pharmaceuticals has higher revenue and earnings than Oric Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.50	-$7.12M	N/A	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

In the previous week, Telix Pharmaceuticals had 2 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 3 mentions for Telix Pharmaceuticals and 1 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 1.89 beat Telix Pharmaceuticals' score of 0.62 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Telix Pharmaceuticals	Positive
Oric Pharmaceuticals	Very Positive

Summary

Telix Pharmaceuticals beats Oric Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Oric Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Arcutis Biotherapeutics currently has a consensus target price of $34.00, indicating a potential upside of 25.93%. Oric Pharmaceuticals has a consensus target price of $18.92, indicating a potential upside of 98.50%. Given Oric Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Oric Pharmaceuticals is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

In the previous week, Arcutis Biotherapeutics had 3 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 4 mentions for Arcutis Biotherapeutics and 1 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 1.89 beat Arcutis Biotherapeutics' score of 0.89 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Arcutis Biotherapeutics	Positive
Oric Pharmaceuticals	Very Positive

Arcutis Biotherapeutics has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Oric Pharmaceuticals has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

95.1% of Oric Pharmaceuticals shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Arcutis Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.98	-$16.14M	-$0.03	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

Summary

Arcutis Biotherapeutics beats Oric Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Oric Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Dyne Therapeutics has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Dyne Therapeutics presently has a consensus price target of $34.17, indicating a potential upside of 63.16%. Oric Pharmaceuticals has a consensus price target of $18.92, indicating a potential upside of 98.50%. Given Oric Pharmaceuticals' higher possible upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Oric Pharmaceuticals' return on equity of -35.33% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

In the previous week, Dyne Therapeutics had 11 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 12 mentions for Dyne Therapeutics and 1 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 1.89 beat Dyne Therapeutics' score of 0.02 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Dyne Therapeutics	Neutral
Oric Pharmaceuticals	Very Positive

Summary

Dyne Therapeutics and Oric Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get Oric Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORIC vs. The Competition

Export

Metric	Oric Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$986.55M	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-6.62	21.75	25.89	24.17
Price / Sales	N/A	334.18	547.76	101.00
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	2.44	8.31	10.75	6.38
Net Income	-$129.47M	$23.92M	$3.58B	$337.00M
7 Day Performance	6.72%	1.93%	1.97%	-0.20%
1 Month Performance	12.78%	-0.41%	-0.24%	-1.40%
1 Year Performance	-7.57%	65.22%	34.39%	27.76%

Oric Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORIC Oric Pharmaceuticals	2.3386 of 5 stars	$9.53 flat	$18.92 +98.5%	-7.6%	$986.55M	N/A	N/A	80	Positive News
BEAM Beam Therapeutics	2.1908 of 5 stars	$35.53 +4.1%	$46.83 +31.8%	+107.2%	$3.51B	$139.74M	N/A	510
NAMS NewAmsterdam Pharma	2.4408 of 5 stars	$30.82 +3.3%	$48.60 +57.7%	+79.0%	$3.49B	$22.50M	N/A	4	News Coverage
TLX Telix Pharmaceuticals	4.578 of 5 stars	$10.00 -0.9%	$21.13 +111.3%	-33.4%	$3.42B	$803.79M	N/A	1,184	Gap Up
ARQT Arcutis Biotherapeutics	3.3247 of 5 stars	$26.66 +1.7%	$34.00 +27.5%	+96.5%	$3.28B	$376.07M	N/A	150

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORIC) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oric Pharmaceuticals (ORIC) Competitors

ORIC vs. BEAM, NAMS, TLX, ARQT, and DYN

How does Oric Pharmaceuticals compare to Beam Therapeutics?

Summary

How does Oric Pharmaceuticals compare to NewAmsterdam Pharma?

Summary

How does Oric Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

How does Oric Pharmaceuticals compare to Arcutis Biotherapeutics?

Summary

How does Oric Pharmaceuticals compare to Dyne Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC vs. The Competition

Oric Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oric Pharmaceuticals (ORIC) Competitors

ORIC vs. BEAM, NAMS, TLX, ARQT, and DYN

How does Oric Pharmaceuticals compare to Beam Therapeutics?

Do analysts prefer ORIC or BEAM?

Does the media favor ORIC or BEAM?

Which has more risk and volatility, ORIC or BEAM?

Do institutionals and insiders hold more shares of ORIC or BEAM?

Is ORIC or BEAM more profitable?

Which has preferable earnings and valuation, ORIC or BEAM?

Summary

How does Oric Pharmaceuticals compare to NewAmsterdam Pharma?

Does the media prefer ORIC or NAMS?

Which has preferable valuation and earnings, ORIC or NAMS?

Which has more risk & volatility, ORIC or NAMS?

Is ORIC or NAMS more profitable?

Do analysts prefer ORIC or NAMS?

Do institutionals & insiders have more ownership in ORIC or NAMS?

Summary

How does Oric Pharmaceuticals compare to Telix Pharmaceuticals?

Which has more volatility & risk, TLX or ORIC?

Do insiders and institutionals believe in TLX or ORIC?

Do analysts recommend TLX or ORIC?

Is TLX or ORIC more profitable?

Which has preferable earnings & valuation, TLX or ORIC?

Does the media favor TLX or ORIC?

Summary

How does Oric Pharmaceuticals compare to Arcutis Biotherapeutics?

Do analysts recommend ARQT or ORIC?

Does the media favor ARQT or ORIC?

Which has more volatility and risk, ARQT or ORIC?

Is ARQT or ORIC more profitable?

Do institutionals & insiders believe in ARQT or ORIC?

Which has stronger valuation & earnings, ARQT or ORIC?

Summary

How does Oric Pharmaceuticals compare to Dyne Therapeutics?

Which has more risk & volatility, DYN or ORIC?

Do analysts recommend DYN or ORIC?

Is DYN or ORIC more profitable?

Do institutionals and insiders believe in DYN or ORIC?

Which has better earnings and valuation, DYN or ORIC?

Does the media favor DYN or ORIC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC vs. The Competition

Oric Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools